Lockerman Financial Group Inc. Sells 800 Shares of Masimo Co. (NASDAQ:MASI)

Lockerman Financial Group Inc. lessened its stake in shares of Masimo Co. (NASDAQ:MASI) by 5.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,600 shares of the medical equipment provider’s stock after selling 800 shares during the quarter. Masimo comprises about 3.1% of Lockerman Financial Group Inc.’s holdings, making the stock its 4th biggest holding. Lockerman Financial Group Inc.’s holdings in Masimo were worth $1,813,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of MASI. Goldman Sachs Group Inc. lifted its position in shares of Masimo by 40.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 175,510 shares of the medical equipment provider’s stock worth $20,572,000 after buying an additional 50,572 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Masimo by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 4,781,343 shares of the medical equipment provider’s stock worth $560,421,000 after buying an additional 26,473 shares during the last quarter. Juncture Wealth Strategies LLC purchased a new stake in shares of Masimo during the 1st quarter worth approximately $298,000. Riverview Trust Co purchased a new stake in shares of Masimo during the 1st quarter worth approximately $25,000. Finally, Cardinal Capital Management lifted its position in shares of Masimo by 25.1% during the 1st quarter. Cardinal Capital Management now owns 14,764 shares of the medical equipment provider’s stock worth $2,168,000 after buying an additional 2,962 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Wall Street Analyst Weigh In

MASI has been the subject of several recent analyst reports. BTIG Research boosted their price objective on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research report on Friday, September 20th. Finally, Piper Sandler upped their price target on shares of Masimo from $160.00 to $165.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Masimo currently has an average rating of “Moderate Buy” and an average target price of $145.33.

Masimo Stock Performance

Masimo stock traded down $0.42 during trading hours on Tuesday, reaching $143.93. 455,070 shares of the stock were exchanged, compared to its average volume of 683,243. The stock has a market cap of $7.65 billion, a P/E ratio of 98.20 and a beta of 0.99. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.15 and a current ratio of 2.09. Masimo Co. has a 52-week low of $75.22 and a 52-week high of $153.93. The firm’s 50 day moving average is $123.91 and its 200 day moving average is $125.01.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.09. The company had revenue of $496.30 million during the quarter, compared to the consensus estimate of $493.92 million. Masimo had a net margin of 3.94% and a return on equity of 14.07%. Masimo’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.62 EPS. Analysts predict that Masimo Co. will post 3.88 EPS for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.